HISAMITSU PHARMACEUTICAL CO.,INC.
久光製薬株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4530
FY2024 (Feb 2025) · J-GAAP · consolidated Source: filing S100VT69
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2024 (Feb 2025) runs Mar 1, 2024 – Feb 28, 2025.
| Gross margin | 58.5% |
|---|---|
| Operating margin | 12.1% |
| Net margin | 13.9% |
| Return on equity | 8.0%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 6.5% |
| Revenue growth (YoY) | 10.1% |
| EPS (basic) | ¥295.57 |
| EPS growth (YoY) | 62.7% |
| Current ratio | 4.32x |
| Equity ratio | 80.6% |
| Book value / share | ¥3,788.47 |
| Free cash flow | ¥5.0B |